ehealth radio network
Episodes
Saturday Aug 12, 2023
Saturday Aug 12, 2023
Sandesh Seth, CEO of Actinium Pharmaceuticals which is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs joins eHealth Radio and the Cancer Information and Health News Channels.
Listen to interview with host Eric Michaels and guest Sandesh Seth discuss the following:
What is unique about Actinium’s radiotherapy approach?
Tell me about Iomab-B, its target population, and how it will affect the patient journey.
Actimab-A is also in AML. How is it different from Iomab-B and what’s the approach here?
What’s next in your pipeline?
Tell me what upcoming catalysts I should expect in the second half of 2023.
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals develops targeted radiotherapies to meaningfully improve survival for people who have failed existing oncology therapies. Advanced pipeline candidates Iomab-B (pre-BLA), an induction and conditioning agent prior to bone marrow transplant, and Actimab-A (National Cancer Institute CRADA pivotal development path), a therapeutic, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. Actinium plans to advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. Actinium's technology platform is the basis for collaborations with Astellas Pharma for solid tumors, AVEO Oncology/LG Chem Life Sciences for HER3 solid tumors, and EpicentRx for its CD47 targeting agent, and several internal programs in solid tumors. Actinium holds more than 200 patents and patent applications.
Website: https://www.actiniumpharma.com
Social Media Links: Linkedin: https://linkedin.com/company/actinium-pharmaceuticals-inc-Facebook: https://facebook.com/people/Actinium-Pharmaceuticals-IncTwitter: https://twitter.com/ActiniumPharma
People also listened to this: The Miracle of Enzymes to Heal Digestive Problems
Friday Jul 28, 2023
Friday Jul 28, 2023
Ram Mukunda and Claudia Grimaldi from IGC Pharma, a clinical stage pharmaceutical company focused on improving the health and well-being of patients affected by Alzheimer’s disease and bringing these therapies to market joins eHealth Radio and the Alzheimer’s Information and Health News Channels.
Listen to interview with host Eric Michaels and guests Ram Mukunda and Claudia Grimaldi discuss the following:
Many people are aware of the symptoms of Alzheimer's including dementia, but many are unaware of that agitation is one of the most common and challenging aspects of care among patients with dementia due to Alzheimer’s disease. Can you explain why?
How does this condition affect those caring for a patient affected by Alzheimer's?
How does your investigational drug IGC-AD1 work to help these patients?
What are the next steps in bringing this drug to market?
What other therapies is IGC Pharma working on in Alzheimer’s?
Ram Mukunda is both the founder and Chief Executive Officer of IGC Pharma. Prior to forming IGC Pharma, he was the President, Chief Executive Officer & Director at India Globalization Capital, Inc., Chairman, President & Chief Executive Officer for Techni Bharathi Pvt Ltd. (a subsidiary of India Globalization Capital, Inc.).
Ram Mukunda previously occupied the position of Council Member at Jamaica Dairy Development Board, Chairman & Chief Executive Officer of Startec Global Communications Corp., Council Member at Harvard Kennedy School of Government and Council Member at Belfer Center for Science & International Affairs.
Ram Mukunda received an undergraduate degree and a graduate degree from the University of Maryland.
Claudia Grimaldi has been with IGC for almost 12 years with increasing responsibilities including managing SEC and NYSE filings, regulatory compliance, and disclosures. She is currently Vice President, Principal Finance Officer, and Chief Compliance Officer. She is also the Managing Director of Hamsa Biochem SAS, our subsidiary in Colombia, as well as a director of our subsidiary in India.
Ms. Grimaldi graduated with a BA in Psychology with high honors from Javeriana University, a top three university in Colombia, and an MBA with high honors from Meredith College in North Carolina. She has completed Executive Education courses on SEC compliance, finance from UVA, and corporate governance from the Columbia Business School.
Website: https://www.igcpharma.com
People also listened to this: Improving skin health is a journey
Tuesday May 23, 2023
Tuesday May 23, 2023
Randy Milby, the Chief Executive Officer and Chairman of Hillstream BioPharma, a biotechnology company developing therapeutic candidates targeting drug-resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death, and immuno-oncology targeted novel biologics joins eHealth Radio and the Cancer Information & Health News Channels.
Listen to interview with host Eric Michaels and guest Randy Milby discuss the following:
Please tell us a bit about your background and Hillstream BioPharma.
What developments are currently in Hillstream’s pipeline?
How does ferroptosis-targeted therapy differentiate from other cancer treatments currently available or under development?
Why is it important to Hillstream to develop drug resistant therapeutics for cancers with few treatment options?
What advice can you share with industry peers, key opinion leaders, or anyone pursuing R&D in the biotechnology space?
Looking ahead, what exciting advances do you think are on the horizon for Hillstream?
Mr. Milby previously served as Chief Executive Officer and Member of the Board of Directors at CorMedix, a publicly traded biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of inflammatory and infectious diseases. He is a seasoned executive who led the increase in market capitalization from $3M to a peak of $350M of Cormedix while improving the company’s financial position with capital raises from equity markets. He oversaw efforts to gain CE Market approval of Neutrolin® in the European Union and held increasing roles of responsibility at Goldman Sachs and Dupont Merck prior in his career.
Website: https://hillstreambio.com
Social Media Links: Facebook: https://facebook.com/HillstreamBioPharma Linkedin: https://linkedin.com/company/hillstream-biopharma Twitter: https://twitter.com/HillstreamB
People also listened to this: Checkable Medical: Revolutionizing Home Healthcare and Telemedicine
Saturday Feb 25, 2023
Saturday Feb 25, 2023
Mark Diamond, Managing Director and CEO at Antisense Therapeutics Limited joins eHealth Radio and the Health News Channel. Antisense is an Australian publicly-listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases.
Listen to host Eric Dye & guest Mark Diamond discuss the following:
Tell us more about Antisense. How is the company specifically developing treatments for Duchenne muscular dystrophy? Describe who is affected and the number of patients that are potentially seeking treatment.
Antisense conducted a new pre-clinical study. What did that involve, what were some of the results? What’s next?
COVID-19 is a part of many people’s lives. There are a variety of new, returning or ongoing symptoms that people experience more than four weeks after getting COVID-19. Tell us more about that.
Antisense is addressing medical needs and also financial opportunities. Tell us about the size of the market and the opportunities.
What's next for Antisense in 2023 and even in 2024? Where can we find out more?
Mark Diamond has over 30 years experience in the pharmaceutical and biotechnology industry. Before joining Antisense Therapeutics Limited as MD and CEO in 2001, Mr. Diamond was employed in the US as Director, Project Planning/Business Development at Faulding Pharmaceuticals. Prior to this he held the positions of Senior Manager, Business Development and In-licensing within Faulding’s European operation based in the UK and International Business Development Manager with Faulding in Australia.
Website: https://www.antisense.com.au
Social Media Links: Twitter: https://twitter.com/antisenselLinkedin: https://linkedin.com/company/antisense-therapeutics-ltd.
People also listened to this: How to Battle Snoring with The Snorinator
Tuesday Aug 30, 2022
Tuesday Aug 30, 2022
Fady Boctor, President and Chief Commercial Officer at Petros Pharmaceuticals, a leading provider of therapeutics for men’s health joins eHealth Radio and the Men's Health and Pharmaceutical Channels.
Listen to interview with host Eric Michaels and guest Fady Boctor discuss the following:
Please give us a bit of background on Petros, its core mission, and how you got started with the company.
What is in your current pipeline of developments?
Please give us a brief overview of the ED market and how Petros aims to bring new treatments to men’s health.
Could you please give us a brief overview of what differentiates Petros from others in the same category?
What recent or upcoming milestones is the company working towards?
Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men's health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues, including, but not limited to, erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie's disease, hormone health, and substance use disorders.
Website: https://www.petrospharma.com
Social Media Links: Facebook: https://facebook.com/PetrosPharmaceuticals Linkedin: https://linkedin.com/company/petros-pharmaceuticals Twitter: https://twitter.com/PetrosPharma
Tuesday Jun 28, 2022
Tuesday Jun 28, 2022
Craig Caceci, Executive Vice President and Managing Director of Terebellum, part of AscellaHealth Family of Companies, based in Dublin, Ireland, offering premier pre-commercialization and market access expertise, supply chain logistics and distribution, and unique pharmaceutical financial solutions, such as loan-based assistance to Life Sciences partners and other industry stakeholders joins eHealth Radio and the Health News Channel.
Listen to interview with host Eric Michaels and guest Craig Caceci discuss the following:
Can you give our listeners some background on your work within Terebellum?
The AscellaHealth Family of Companies recently announced Terebellum’ s plans for expansion into Germany and the United Kingdom. Will this expanded international footprint come with any additional services and if yes, will they differ from those offered in the US?
How will this expanded marketplace impact the scope of opportunities now available to pharmaceutical companies and what impact will these services have on lives of patients with complex chronic conditions or rare diseases?
From the specialty drug manufacturers’ perspective, what are the advantages of accessing services from a robust resource that includes pre-commercialization to fulfilment programs with the ability to tailor services to individual unmet needs?
I understand Terebellum has extensive payer expertise within Europe. How does working the Terebellum help ensure seamless product access for patients?
Please explain how Terebellum’s services are offered as both an inclusive package or a la carte.
Craig Caceci, Executive Vice President and Managing Director of Terebellum, part of AscellaHealth Family of Companies. Terebellum is a Dublin, Ireland based subsidiary of AscellaHealth representing AscellaHealth’s global footprint throughout Europe. The premier group purchasing services, unique pharmaceutical financial solutions, payer and market access expertise and custom pull-through programs targeted to Life Sciences partners and other industry stakeholders ensure optimal cost savings and enhanced clinical outcomes. Terebellum’s leadership team has the deep payer, reimbursement, marketing, and financial expertise needed to provide a consultative approach for branded specialty products to be brought to market successfully.
Website: https://ascellahealth.com
Linkedin: https://linkedin.com/company/ascellahealth
Friday May 06, 2022
Friday May 06, 2022
Michael Baldzicki, Chief Brand Officer at AscellaHealth, a global specialty pharmacy and healthcare solutions company joins eHealth Radio and the Healthcare and Pharmaceutical Information Channels to talk about the company’s comprehensive suite of Specialty Pharmacy services for pharmaceutical/biotech manufacturers.
Listen to interview with host Eric Michaels and guest Michael Baldzicki discuss the following:
Can you give our listeners information on your background and role with AscellaHealth?
Please describe the AscellaHealth business model and how the company serves life sciences in the specialty pharmacy and healthcare industry.
AscellaHealth has an exciting new strategic alliance with Optime Care. Can you tell our listeners what this partnership means for others in the industry?
AscellaHealth recently came out with some expanded services. Can you explain these new offerings and their benefits for key market segments that AscellaHealth serves?
In the current healthcare environment, it seems people are lacking customizable options. Can you speak to the flexibility of AscellaHealth’s solutions and how this ultimately serves to enhance outcomes of branded products?
As chief brand officer for AscellaHealth, Mike ensures the success of the widest variety of strategic projects across departmental segments, and other business development initiatives that cultivate opportunities that affect client segments.
With more than 21+ years of specialty pharmacy, pharmaceutical and biotech industry experience, including roles in national and regional managed markets, specialty supply channels, sales management and specialty brand management. Mike offers strategic insight into specialty pharmacy trends, distribution, contracting, reimbursement, and the application of health outcomes and economic evidence to prove value proposition. He is a recognized leader in the specialty pharmaceutical market for developing and implementing key payer and specialty pharmacy agreements that result in documented savings for specialty market segments.
Mike is active in the biotech community and is an advisor/faculty member of the Academy of Managed Care Pharmacy (AMCP) for Specialty Pharmacy Advisory Group & Biosimilars Partnership Forum, NCPDP Specialty Pharmacy Stakeholder Action Group, Faulty Board Member of the American Journal of Managed Care (AJMC) Specialty Pharmacy for ACOs and was 2014 Editorial Board Member for Specialty Pharmacy Times.
He has published abstracts and articles surrounding plasma-based infusion therapy, and managed markets and specialty pharmacy. He has spoken at a variety of seminars and WebEx’s within specialty groups and other industry related settings.
Mike earned a Bachelor of Arts in Business Management and a Certificate in Clinical Research Compliance and Management (CRCM). He has completed programs in leadership development at Harvard University, Brooks Group, Miller Heiman Account Management and MD Anderson Center Cancer Courses.
Website: https://ascellahealth.com
Linkedin: https://linkedin.com/company/ascellahealth
Thursday Jan 21, 2021
Thursday Jan 21, 2021
Anthony DiTonno CEO of Tenax Therapeutics, a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs joins eHealth Radio and the Health News and Pharmaceutical Channels.
Listen to interview with host Eric Michaels & guest Anthony DiTonno discuss the following:
Can you tell me a bit about yourself and how you got interested in the healthcare and pharmaceutical industry?
What products are in the pipeline?
Could you please tell us about Tenax's HELP study?
Please let us and talk a little about Levosimendan.
Anthony A. DiTonno has served as CEO since 2018 and as a director since December 2011. From 2013 until filling the role as Tenax CEO, Mr. DiTonno served as Chief Executive Officer of Avantis Medical Systems, Inc., a medical device company that develops and manufactures catheter-based endoscopic devices.
From April 2003 until December 2011, Mr. DiTonno was President and Chief Executive Officer of Neurogesx Inc., a biopharmaceutical company based in the San Francisco Bay area (“Neurogesx”). During his time at Neurogesx, Mr. DiTonno also served on its board of directors.
Mr. DiTonno has funded companies through a variety of financial arrangements including private and public financing, partnerships and debt. He has also been successful in gaining regulatory approvals in both the United States and European Union.
Previously, he was Executive Vice President of Marketing and Sales at Enteric Medical Technologies Inc., which was acquired by Boston Scientific Company; President and Chief Executive Officer of Lifesleep Systems, Inc.; and Vice President and General Manager of Olcassen Pharmaceuticals, which was sold to Watson Laboratories.
Early in his career, he held a variety of positions of increasing responsibility at Rorer Group, Inc. (Rhône Poulenc Rorer) and Wyeth Laboratories. Mr. DiTonno received an M.B.A. from Drexel University and a B.S. in Business Administration from St. Joseph’s University.
Website: www.tenaxthera.com
Saturday Dec 19, 2020
Saturday Dec 19, 2020
Chris Bunka, the CEO of Lexaria Bioscience, a Lexaria Bioscience Corp.’s proprietary drug delivery technology, DehydraTECH™, that improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing joins eHealth Radio and the Health News and Pharmaceutical Channels.
Listen to interview with host Eric Michaels and guest Chris Bunka discuss the following:
Please tell us a little bit about yourself, how Lexaria Bioscience started and the development of the company’s technology?
What exactly are DehydraTECH and its benefits?
Can you talk about your recent announcement with British American Tobacco?
What are fat-soluble active molecules and how can your technology lower overall dosing with pharmaceutical ingredients?
What type of drugs and areas can DehydraTECH increase bio-absorption?
Lexaria Bioscience Corp.’s (OTCQX: LXRP, CSE: LXX) proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules.
DehydraTECH increases bio-absorption by up to 5-10x, reduces time of onset from 1 - 2 hours to 10 - 20 minutes, and masks unwanted tastes for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine, and other molecules.
Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.
Website: lexariabioscience.com
Social Media Links: Facebook: facebook.com/lexariabioscience Linkedin: linkedin.com/company/lexaria-bioscience Twitter: twitter.com/LexariaBioCorp
Saturday Dec 05, 2020
Saturday Dec 05, 2020
Myron Holubiak, President and CEO of Citius Pharmaceuticals, and Leonard Mazur, Chairman of the Board at Citius Pharmaceuticals, a specialty late-stage pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infectives and cancer care joins eHealth Radio and the Cancer Information and Health News Channels.
Listen to interview with host Eric Michaels and guests Myron Holubiak & Leonard Mazur discuss the following:
Please give us an overview of catheter-related bloodstream infections (CRBSIs) and central venous catheters (CVCs).
Who is at Risk for Catheter-Related Bloodstream Infections (CRBSIs)?
Please give us a brief description of Minolok and how does it help the standard of care in the management of CRBSIs?
Give us a brief description of our NoveCite subsidiary and the impact of Covid 19 patients w ARDS. What is your technology and why is it different?
How is the development of MinoWrap for mastectomies progressing after your collaboration w MD Andersen?
Why did the both of you invest 26.5 million into the company?
Mr. Mazur is an accomplished entrepreneur and pharmaceutical industry executive with notable accomplishments in founding, building and creating value and returns for investors. Mr. Mazur was the Chairman of Leonard Meron Biosciences, Inc. prior to its merger with Citius in March 2016. He is the cofounder and Vice Chairman of Akrimax Pharmaceuticals, LLC (“Akrimax”), a privately held pharmaceutical company specializing in producing cardiovascular and general pharmaceutical products. Akrimax was founded in September 2008, and has successfully launched prescription drugs while acquiring drugs from major pharmaceutical companies. From January 2005 to May 2012, Mr. Mazur also co-founded and served as the Chief Operating Officer of Triax Pharmaceuticals LLC (“Triax”), a specialty pharmaceutical company producing prescription dermatological drugs. Prior to joining Triax, he was the founder, and, from 1995 to 2005, Chief Executive Officer, of Genesis Pharmaceuticals, Inc. (“Genesis”), a dermatological products company that marketed its products through dermatologists’ offices, and co-promoted products for major pharmaceutical companies. In 2003, Mr. Mazur successfully sold Genesis to Pierre Fabre, a leading pharmaceutical company.
Mr. Mazur has extensive sales, marketing and business development experience from his tenures at Medicis Pharmaceutical Corporation, as Executive Vice President, ICN Pharmaceuticals, Inc., as Vice President, Sales & Marketing, Knoll Pharma (a division of BASF), and Cooper Laboratories, Inc.
Mr. Mazur is a member of the Board of Trustees of Manor College, and is a recipient of the Ellis Island Medal of Honor. Mr. Mazur received both his BA and MBA from Temple University, and has served in the US Marine Corps Reserves.
Mr. Holubiak has extensive experience in managing and leading both large and emerging pharmaceutical and life sciences companies. Mr. Holubiak was co-founder, director and CEO of Leonard Meron Biosciences, Inc. prior to its merger with Citius in March 2016. Mr. Holubiak was the President of Roche Laboratories, Inc. (“Roche”), a major research-based pharmaceutical company, from December 1998 to August 2001.
Prior to that, he held sales and marketing positions at Roche during his 19-year tenure there. As President of Roche, Mr. Holubiak helped transform Roche Labs into a leading antibiotic and biotechnology company. He was also founder of Emron, Inc., a health economics and managed care consulting company, and helped to create the Academy of Managed Care Pharmacy (AMCP). Mr. Holubiak was also a director of Bioscrip, Inc., a national home infusion company, from 2002 through 2016, and served as its Chairman of the Board from 2012 through 2016.
Since July 2010, Mr. Holubiak has served as a member of the Board of Directors of Assembly Biosciences, Inc. (“Assembly”) and its predecessor, Ventrus Biosciences, Inc. Mr. Holubiak is also a trustee of the Academy of Managed Care Pharmacy Foundation. He received a BS in Molecular Biology and Biophysics from the University of Pittsburgh; he received advanced business training from the Harvard Business School and the University of London, as well as advanced training in health economics from the University of York’s Centre for Health Economics.
Website: citiuspharma.com